Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHGU2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,901
Award facts
- Contract value 100% obligated
- $37,901.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $37,901.28 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The award, issued on December 9, 2025, with an ultimate completion date of December 31, 2025, was made without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which carries a $499.999 billion ceiling value and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's medical supply chain, with this delivery order representing one of numerous orders issued by the company since October 2025. The company's product portfolio encompasses an extensive range of pharmaceuticals and biologics, including branded and generic prescription medications, over-the-counter drugs, vaccines, and specialty pharmaceutical products. The PPV-G GEN V program, representing a $30.3 billion acquisition strategy, establishes DMS Pharmaceutical Group as one of multiple regional prime vendor contractors positioned to support recurring medical supply needs of military healthcare facilities worldwide. No subcontractors are identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FHGU2?
SPE2DR26FHGU2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FHGU2 worth?
The government has obligated $37,901 on SPE2DR26FHGU2.
Is contract SPE2DR26FHGU2 an order under another contract?
Yes. SPE2DR26FHGU2 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGU2 competed?
The extent of competition for SPE2DR26FHGU2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award